Compare CCLD & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCLD | PYPD |
|---|---|---|
| Founded | 1999 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.6M | 107.0M |
| IPO Year | 2013 | 2014 |
| Metric | CCLD | PYPD |
|---|---|---|
| Price | $1.99 | $5.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $7.33 | ★ $11.75 |
| AVG Volume (30 Days) | ★ 205.3K | 81.6K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 135.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $120,499,000.00 | N/A |
| Revenue This Year | $8.14 | N/A |
| Revenue Next Year | $9.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.72 | N/A |
| 52 Week Low | $1.93 | $3.10 |
| 52 Week High | $3.81 | $5.73 |
| Indicator | CCLD | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 40.85 | 45.12 |
| Support Level | N/A | $5.00 |
| Resistance Level | $2.42 | $5.07 |
| Average True Range (ATR) | 0.07 | 0.26 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 33.96 | 32.50 |
CareCloud Inc delivers flexible, tech-enabled solutions for healthcare providers of all sizes and multi-specialties across the U.S. It is a healthcare technology company offering cloud-based solutions that simplify clinical, administrative, and financial workflows for medical practices of all sizes. Its comprehensive suite includes Electronic Health Records (EHRs), Practice Management, Revenue Cycle Management (RCM), Medical Billing, Telehealth, and Patient Experience solutions. The group helps practices increase efficiency, improve patient care, and drive sustainable growth-all while ensuring HIPAA compliance and seamless integration. The operating segments of the group are Healthcare IT, which is the key revenue-generating segment, and Medical Practice Management.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.